"10.1371_journal.pone.0031573","plos one","2012-02-20T00:00:00Z","Pia Larsson; Erik Ulfhammer; Mia Magnusson; Niklas Bergh; Sebastian Lunke; Assam El-Osta; Robert L Medcalf; Per-Arne Svensson; Lena Karlsson; Sverker Jern","The Wallenberg Laboratory for Cardiovascular Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Epigenetics in Human Health and Disease Laboratory, Baker IDI Heart and Diabetes Institute, The Alfred Medical Research and Education Precinct, Melbourne, Victoria, Australia; Australian Centre for Blood Diseases, The Alfred Medical Research and Education Point, Monash University, Melbourne, Victoria, Australia; Sahlgrenska Center for Cardiovascular and Metabolic Research, Department of Molecular and Clinical Medicine, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden","Conceived and designed the experiments: PL EU SL AE RLM PS LK SJ. Performed the experiments: PL EU MM NB. Analyzed the data: PL EU MM NB SL PS. Contributed reagents/materials/analysis tools: SL AE RLM PS SJ. Wrote the paper: PL EU MM NB LK SJ.","PL, EU, MM, NB, and SJ have completed and submitted two United States provisional patent applications (US 61/464, 809 and US 61/464, 776) claiming the use of valproic acid and other clinically used HDAC inhibitors as stimulators of endogenous fibrinolysis. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","02","Pia Larsson","PL",10,TRUE,8,4,6,6,TRUE,TRUE,FALSE,0,NA,FALSE
